Argus Research Upgrades Regeneron Pharmaceuticals to Buy, Announces $850 Price Target

Argus Research has upgraded Regeneron Pharmaceuticals (NASDAQ: REGN) from a 'Hold' rating to 'Buy'. The firm has set a price target of $850 for the stock, indicating a positive outlook for the company's performance.